Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.46 |
| ▸ | ADA | P00813 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18270599 | 0.76 | RECQL (0.42) | HDAC8KMOELANERECQLMEN1 | |
| SCHEMBL17188069 | 0.75 | P2RX7 (0.47) | HDAC8KMOELANERECQLMEN1 | |
| Oxalic Acid SCHEMBL14810479 | 0.73 | KMO (0.46) | HDAC8KMOELANERECQLMEN1 | |
| SCHEMBL4553548 | 0.73 | KMT2A (0.50) | HDAC8KMOELANERECQLMEN1 | |
| SCHEMBL30066427 | 0.73 | KMT2A (0.50) | HDAC8KMOELANERECQLMEN1 | |
| SCHEMBL8725006 | 0.73 | KMO (0.43) | HDAC8KMOELANERECQLMEN1 | |
| SCHEMBL30918021 | 0.72 | MEN1 (0.44) | KMOELANERECQLMEN1NPC1 | |
| SCHEMBL18268988 | 0.72 | MEN1 (0.44) | KMOELANERECQLMEN1NPC1 | |
| SCHEMBL31326725 | 0.72 | KMO (0.42) | HDAC8KMOELANERECQLMEN1 | |
| SCHEMBL18135255 | 0.72 | KMO (0.42) | HDAC8KMOELANERECQLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2023-07-25 | — | — | US | disclosed |
| CN-110325528-B | 2-benzopyrazinyl-N-heteroaryl-2-phenyl-acetamide compounds | 豪夫迈·罗氏有限公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3558967-B1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-03-02 | — | — | EP | disclosed |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10882848-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | HOFFMANN-LA ROCHE, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3558967-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2019-10-30 | — | — | EP | disclosed |
| CN-110325528-A | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | 豪夫迈·罗氏有限公司 | 2019-10-11 | — | — | CN | disclosed |
| US-20190308955-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2018115218-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708354-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | HDAC8 1109/4885ADA 2089/4885KMO 4236/4885 |
| US-10882848-B2 | 2-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compounds | EGFR, ERBB2, ERBB3 | HDAC8 1109/4885ADA 2089/4885KMO 4236/4885 |
| US-20210070739-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | HDAC8 1109/4885ADA 2089/4885KMO 4236/4885 |
| US-20190308955-A1 | 2-BENZOPYRAZINYL-N-HETEROARYL-2-PHENYL-ACETAMIDE COMPOUNDS | EGFR, ERBB2, ERBB3 | HDAC8 1109/4885ADA 2089/4885KMO 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.